Orion Oyj (ORINF)
USD 48.65
(0.0%)
USD 48.65
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 548.5 Million EUR | -7.89% |
| 2022 | 595.5 Million USD | 43.11% |
| 2021 | 416.12 Million EUR | -11.5% |
| 2020 | 470.21 Million EUR | 63.44% |
| 2019 | 287.69 Million EUR | -22.99% |
| 2018 | 373.6 Million EUR | -0.59% |
| 2017 | 375.8 Million EUR | -10.84% |
| 2016 | 421.5 Million EUR | -14.25% |
| 2015 | 491.55 Million EUR | 1.02% |
| 2014 | 486.6 Million EUR | 4.62% |
| 2013 | 465.1 Million EUR | 42.58% |
| 2012 | 326.2 Million EUR | 16.83% |
| 2011 | 279.2 Million EUR | 0.29% |
| 2010 | 278.4 Million EUR | -3.33% |
| 2009 | 288 Million EUR | 4.01% |
| 2008 | 276.9 Million EUR | 105.87% |
| 2007 | 134.5 Million EUR | -6.98% |
| 2006 | 144.6 Million EUR | -73.95% |
| 2005 | 555 Million EUR | -15.38% |
| 2004 | 655.9 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 683.3 Million EUR | -1.73% |
| 2024 Q2 | 695.3 Million EUR | -7.69% |
| 2024 Q1 | 812.7 Million EUR | 37.29% |
| 2023 Q3 | 562.05 Million USD | -4.56% |
| 2023 Q2 | 588.89 Million USD | -3.73% |
| 2023 Q1 | 611.7 Million USD | -4.02% |
| 2023 Q4 | 605.4 Million EUR | 7.71% |
| 2023 FY | 548.5 Million EUR | -7.89% |
| 2022 Q4 | 637.33 Million USD | 9.17% |
| 2022 FY | 595.5 Million USD | 43.11% |
| 2022 Q1 | 584.9 Million EUR | 59.72% |
| 2022 Q2 | 546 Million EUR | -6.65% |
| 2022 Q3 | 583.8 Million EUR | 6.92% |
| 2021 Q2 | 406.64 Million EUR | -37.85% |
| 2021 Q4 | 366.2 Million EUR | 17.03% |
| 2021 Q3 | 312.9 Million EUR | -23.05% |
| 2021 Q1 | 654.28 Million EUR | 70.25% |
| 2021 FY | 416.12 Million EUR | -11.5% |
| 2020 Q1 | 401.1 Million EUR | 56.5% |
| 2020 FY | 470.21 Million EUR | 63.44% |
| 2020 Q2 | 396.5 Million EUR | -1.15% |
| 2020 Q3 | 339.4 Million EUR | -14.4% |
| 2020 Q4 | 384.3 Million EUR | 13.23% |
| 2019 FY | 287.69 Million EUR | -22.99% |
| 2019 Q4 | 256.3 Million EUR | 16.45% |
| 2019 Q2 | 258.6 Million EUR | -56.38% |
| 2019 Q3 | 220.1 Million EUR | -14.89% |
| 2019 Q1 | 592.9 Million EUR | 58.7% |
| 2018 Q1 | 497.5 Million EUR | 32.38% |
| 2018 FY | 373.6 Million EUR | -0.59% |
| 2018 Q4 | 373.6 Million EUR | 6.17% |
| 2018 Q3 | 351.9 Million EUR | -5.02% |
| 2018 Q2 | 370.5 Million EUR | -25.53% |
| 2017 Q1 | 442.5 Million EUR | 4.98% |
| 2017 FY | 375.8 Million EUR | -10.84% |
| 2017 Q4 | 375.8 Million EUR | 0.05% |
| 2017 Q3 | 375.6 Million EUR | -5.44% |
| 2017 Q2 | 397.2 Million EUR | -10.24% |
| 2016 Q1 | 612.8 Million EUR | 35.43% |
| 2016 FY | 421.5 Million EUR | -14.25% |
| 2016 Q4 | 421.5 Million EUR | 2.88% |
| 2016 Q3 | 409.7 Million EUR | -0.73% |
| 2016 Q2 | 412.7 Million EUR | -32.65% |
| 2015 Q3 | 468.9 Million EUR | -2.94% |
| 2015 FY | 491.55 Million EUR | 1.02% |
| 2015 Q4 | 452.5 Million EUR | -3.5% |
| 2015 Q2 | 483.1 Million EUR | -27.73% |
| 2015 Q1 | 668.5 Million EUR | 37.38% |
| 2014 Q2 | 478.9 Million EUR | -24.57% |
| 2014 Q3 | 447.9 Million EUR | -6.47% |
| 2014 Q4 | 486.6 Million EUR | 8.64% |
| 2014 FY | 486.6 Million EUR | 4.62% |
| 2014 Q1 | 634.9 Million EUR | 36.51% |
| 2013 Q2 | 460.3 Million EUR | -15.76% |
| 2013 Q1 | 546.4 Million EUR | 67.5% |
| 2013 FY | 465.1 Million EUR | 42.58% |
| 2013 Q4 | 465.1 Million EUR | 3.49% |
| 2013 Q3 | 449.4 Million EUR | -2.37% |
| 2012 Q3 | 323.2 Million EUR | -3.58% |
| 2012 Q2 | 335.2 Million EUR | -38.46% |
| 2012 Q1 | 544.7 Million EUR | 95.09% |
| 2012 FY | 326.2 Million EUR | 16.83% |
| 2012 Q4 | 326.2 Million EUR | 0.93% |
| 2011 Q2 | 263 Million EUR | -42.06% |
| 2011 Q3 | 253.1 Million EUR | -3.76% |
| 2011 Q4 | 279.2 Million EUR | 10.31% |
| 2011 Q1 | 453.9 Million EUR | 63.04% |
| 2011 FY | 279.2 Million EUR | 0.29% |
| 2010 FY | 278.4 Million EUR | -3.33% |
| 2010 Q3 | 264.6 Million EUR | -3.08% |
| 2010 Q4 | 278.4 Million EUR | 5.22% |
| 2010 Q1 | 435.2 Million EUR | 51.11% |
| 2010 Q2 | 273 Million EUR | -37.27% |
| 2009 FY | 288 Million EUR | 4.01% |
| 2009 Q4 | 288 Million EUR | 0.0% |
| 2008 FY | 276.9 Million EUR | 105.87% |
| 2007 FY | 134.5 Million EUR | -6.98% |
| 2006 Q4 | 144.6 Million EUR | 0.0% |
| 2006 FY | 144.6 Million EUR | -73.95% |
| 2005 FY | 555 Million EUR | -15.38% |
| 2004 FY | 655.9 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AstraZeneca PLC | 61.86 Billion USD | 99.113% |
| Bristol-Myers Squibb Company PFD CONV 2 | 65.67 Billion USD | 99.165% |
| CSPC Pharmaceutical Group Limited | 1.53 Billion USD | 64.379% |
| Clarus Therapeutics Holdings, Inc. | 67.62 Million USD | -711.067% |
| Novartis AG | 53.19 Billion USD | 98.969% |
| PT Kalbe Farma Tbk. | 255.94 Million USD | -114.308% |